Registry of Lobbyists
Total Number of Communication Reports: 5
Monthly communication reports in the last 6 months: 0
| Subject matters | Details | Categories |
|---|---|---|
|
Health
|
C-64, An act respecting pharmacare - discussions around the structuring and implementation of a national pharmacare program.
|
Legislative Proposal, Bill or Resolution, Policies or Program
|
|
Health
|
Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food & Drug Act.
|
Legislative Proposal, Bill or Resolution
|
|
Economic Development, Health, International Trade
|
Free trade treaty agreement as it relates to the Canada/US Free Trade Agreement and free trade negotiations as it relates to Columbia, India, and the European Union.
|
Policies or Program
|
|
Economic Development, Federal-Provincial Relations, Health, Industry, Intellectual Property
|
Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly's business.
|
Regulation
|
|
Health, Intellectual Property
|
Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.
|
Legislative Proposal, Bill or Resolution
|
|
Economic Development, Federal-Provincial Relations, Health, Industry, Intellectual Property
|
Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.
|
Regulation
|
|
Economic Development, Federal-Provincial Relations, Health, Industry
|
Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry.
|
Policies or Program
|
|
Health, International Trade
|
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
|
Policies or Program
|
|
Economic Development, Health
|
Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Policies or Program
|
|
Economic Development, Federal-Provincial Relations, Health, Industry, Internal Trade, Science and Technology
|
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
|
Policies or Program
|
Address:
P. O. Box 73, Exchange Tower 130 King Street West, Suite 900 Toronto, ON Canada
Toronto, ON M5X 1B1
Canada
Telephone number:
416-699-7222
Jill Daley, General Counsel and Vice President, Corporate Affairs
Eli Lilly Canada Inc. is not a coalition.
The activities of Eli Lilly Canada Inc. are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Eli Lilly Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
ANDRE ALBINATI | Public offices held
Firm: Earnscliffe Strategy Group